One Fix for Greater Social Mobility in the U.S.: Early

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
One Fix for Greater Social Mobility in the U.S.: Early Interventions

LOS ANGELES, CA--(Marketwired - July 28, 2016) - Richard Reeves and Isabel Sawhill, both senior fellows in economic studies at the Brookings Institution in Washington, dispute the widespread conviction that the opportunity to move up the socioeconomic ladder through hard work is alive and well in America. "American children do not have exceptional opportunities to get ahead," they conclude. Worse, they fear that, "the consequences of gaps in children's initial circumstances might embed themselves in the social fabric over time, leading to even less social mobility in the future."

But the researchers do offer hope. Using the Social Genome Model and its rich data base pioneered at Brookings, they find that intervening early and often in a child's life has a surprisingly big impact. The gap of almost 20 percentage points in the chances of low-income and high-income children reaching the middle class on their own by age 40 shrinks to 6 percentage points.

Also in the latest Milken Institute Review, and available at MilkenReview.org:

Larry Fisher, a business journalist who is a frequent contributor to The New York Times, brings us up to date on the economics and politics of carbon capture and storage as a means of slowing climate change. "Nobody seems to love carbon capture," he writes. "On the left, climate change advocates lobby pretty exclusively for renewables and energy conservation -- the eat-your-spinach approach. On the right, at least in the United States, climate change is still claimed to be a hoax perpetuated by liberals who don't want Americans to drive SUVs." But in light of the narrowing options, Fisher predicts "an awakening among environmentalists that achieving carbon reduction goals will require an 'all of the above' strategy."

Barry Eichengreen, an economist at the University of California, Berkeley, reconsiders the uses (and abuses) of government controls on international capital movements. "If the circumstances under which capital controls are useful are clear," he writes, "why are economists still so skeptical?" While a number of countries including Brazil, Uruguay and Thailand have used controls with care and some success, "worries persist that capital controls create a breeding ground for both corruption and distortions in resource allocation."

Frank Rose, a senior fellow at Columbia University School of the Arts, casts a gimlet eye on what Harvard Business School prof Clayton Christensen's "disruption theory" -- an explanation for why rich, seemingly well run corporations have a way of getting knocked off by upstarts. "In the business world, it was as if Christensen had bottled lightning," recounts Rose. "But disruption has been hard to get right, even for Christensen. A decade ago, when Apple was racking up win after win, he consulted his theory and saw failure right around the corner…"

Steve Radelet, the former chief economist at US Agency for International Development, takes the measure of slackening buoyancy in emerging markets. "The pause in breakneck growth now being experienced in the developing world is certainly costly," he writes. "But it's only a detour on a path toward global economic convergence that should be celebrated and supported. Our future -- as well as theirs -- depends on it."

Ross DeVol and Sindhu Kubendran, researchers at the Milken Institute, document the economic consequences of the reality that two-thirds of the victims of dementia in America are women. "This unequal societal burden is almost certain to increase rapidly in light of the explosive rise in the numbers of very old (80+) Americans," they write. "Indeed, we estimate that the purely pecuniary costs of caring for women with dementia will add up to $5.1 trillion (in 2012 dollars) through 2040. Even if you apply a discount rate to these costs…that still adds up to real money, not to mention an ocean of human misery."

Mikhail Fridman, the chairman of LetterOne, a Luxembourg-based investment group, and Anatole Kaletsky, the chairman of the Institute for New Economic Thinking, a New York-based think tank, explore the difficulties emerging-market countries are having in rekindling growth. Fridman is betting that India has the best prospects for a breakout because, for all its warts, the economy is underpinned by an innovation-friendly culture.

Javier Ekboir, a Buenos Aires-based consultant, revisits the view that Southeast Asia is the template for economic development in the late-starters. "International organizations still argue that expansion of agriculture in developing countries, especially small farms, is necessary to trigger growth in other sectors," Ekboir writes. "But a growing number of economists (including me) believe that today's socio-economic dynamics are completely different from those prevailing even 40 years ago, and that a new set of factors ranging from globalization to technological and organizational advancement are the new catalysts of growth." The focus of aid should thus shift to "developing the capacities of rural inhabitants so that they can find non-agricultural jobs in increasingly diverse rural economies."

In an excerpt from his take-no-prisoners book The End of Alchemy, Mervyn King, the former head of the Bank of England who directed monetary policy during the financial crisis, offers an ambitious plan for preventing the next financial collapse.

About

The Milken Institute is a nonprofit, nonpartisan think tank determined to increase global prosperity by advancing collaborative solutions that widen access to capital, create jobs and improve health. It does this through independent, data-driven research, action-oriented meetings and meaningful policy initiatives.

milkeninstitute.org
@milkeninstitute
@milkenreview

Contact
Conrad Kiechel
Managing Director, Communications
(310) 570-4668
ckiechel@milkeninstitute.org

Scroll down for more posts ▼

Top 10 Most Recent News Articles

WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 188

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine

Updated Category News Views 384

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 260

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 267

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 392

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early

Updated Category News Views 382

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 371

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading
El Pollo Loco Faces Class Action Over Wage Practices

Updated Category News Views 472

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 344

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 433

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
/news?page=2">More News Articles